Why stem cells could be the medical innovation of the century – World Economic Forum
Posted: January 16, 2020 at 1:48 pm
Right now, your bodys stem cells are working hard replacing your skin every two weeks, creating new red and white blood cells and completing thousands of other tasks essential to life. They are your own personalized fountain of youth.
Scientists generally agree that a stem cell should be able to do both of the following:
One theory of ageing suggests that between the ages of 30 and 50, our stem cells reach a turning point and start to decline in number and function. This results in the typical features associated with ageing.
There does not seem to be a single discoverer of stem cells. Accounts date back to the 1800s and even further, but the first successful medical procedure was a bone marrow transfusion in 1939. Advances in immunology led to donor matching, initially via siblings and close relatives. Unrelated donor matching flourished in the 1970s, alongside donor registries.
In the 1980s, scientists identified embryonic stem cells in mice, leading to the 1997 cloning of Dolly the Sheep. This created immense interest for human and medical applications and a backlash in the US as federal R&D funding was essentially halted in 2001.
In 2012, a Nobel Prize was awarded for the earlier discovery of induced pluripotent stem cells (iPS). Essentially, they return potency and self-renewal properties to mature non-stem cells, essentially making them act like stem cells again.
In the decade between 2010 and 2019, the first wave of stem cell start-ups emerged, alongside R&D programmes at many large pharmaceutical companies, leading to innovation and the first human clinical trials for iPS and other related therapies.
According to Q3 2019 data from the Alliance for Regenerative Medicine, there are 959 regenerative medicine companies worldwide sponsoring 1,052 active clinical trials; 525 of these companies are in North America, 233 in Europe and Israel, and 166 in Asia. In aggregate, $7.4 billion has been invested in regenerative medicine companies in 2019; $5.6 billion of which has been dedicated to gene and gene-modified cell therapy, $3.3 billion in cell therapy, and $114 million in tissue engineering.
Overview of the cancer stem cells market
Perhaps most excitingly, curative therapies are hitting the market and the results are astonishing: 60% of Acute Lymphoblastic Leukemia patients taking Novartis Kymirah showed a complete response (no traces of cancer) and were declared in full remission. Meanwhile, 75% of patients with Transfusion-Dependent -Thalassaemia treated with bluebird bios Zynteglo achieved independence from transfusions. Perhaps most astonishingly, 93% of spinal muscular atrophy patients treated with Novartis Zolgensma were alive without permanent ventilation 24 months after treatment. We should expect more medical breakthroughs in the coming years.
New science, new start-ups: several companies in the sector have gone public or been acquired. These exits led to the recycling of talent and capital into new companies. Because the science and commercial systems have also advanced, the companies in the next wave are pursuing bigger challenges, driving innovation, with even greater resources.
Patients are eager: the current market for stem cell therapies is growing at 36% per year, though it will rapidly expand when a breakthrough occurs toward the treatment of a non-communicable disease (such as cancer, diabetes, heart disease) or a lifestyle factor (for example, growing hair in the correct places, expanding cognitive abilities or increasing healthy lifespan).
New R&D models: funding is flowing into the sector from large companies, VC funds, and institutions such as the California Institute for Regenerative Medicine (CIRM) and New York State Stem Cell Science programme (NYSTEM). Some of the leading university R&D platforms include the Center for the Commercialization of Regenerative Medicine in Toronto, the Stanford Institute for Stem Cell Biology and Regenerative Medicine, the Oxford Stem Cell Institute, and most notably, the Harvard Stem Cell Institute (HSCI).
Founded in 2004, HSCI has established a phenomenal track record. It provided the first $200,000 in funding to Derrick Rossis lab, which inspired the largest biotech IPO to date. HSCI scientists were also co-founders or principals in the three most prominent gene-editing companies (CRISPR Tx, Intellia and Editas), the combined $1.55-billion True North/iPierian acquisitions and the recent $950-million acquisition of Semma Tx, Frequency Tx, Fate Tx, Epizyme Inc., and Magenta Tx.
For the casual investor, Evercore ISI is building a Regenerative Medicine Index, which may be the simplest way to build a portfolio. For institutions and those with deeper pockets, regenerative medicine funds are forming, including the Boston-centric Hexagon Regenerative Medicine Fund, which aims to create companies out of the Harvard Stem Cell Institute.
Caveat emptor. Though patients needs are immediate, those seeking treatments should think very carefully about the risks. There are many dubious clinics touting expensive stem cell treatments and some patients have experienced horrifying complications. Dr. Paul Knoepfler of UC-Davis has written a practical and scientifically accurate guide, a strongly recommended read if you or a family member are considering treatment or a clinical trial.
The leading causes of death in 1900 were mostly infectious/communicable diseases. While the prevalence of most causes has diminished, the largest increases include heart disease (+40%) and cancer (+300%). Granted, this is partly due to doubling life expectancy and a lack of death from other causes. However, given time and resources, scientists and physicians may cure these challenging diseases.
Total disease burden by disease or injury
Today, six of the seven leading causes of death are non-communicable diseases (heart disease, stroke, lung diseases, cancer, Alzheimers disease and diabetes). Based on the early promise mentioned above, regenerative medicine may be our best hope to solve the great non-communicable diseases of our time, and perhaps the single most transformative medical innovation in a century.
License and Republishing
World Economic Forum articles may be republished in accordance with our Terms of Use.
The views expressed in this article are those of the author alone and not the World Economic Forum.
Excerpt from:
Why stem cells could be the medical innovation of the century - World Economic Forum
- Abu Dhabi Stem Cells Centre partners with Rege Nephro and Kyoto University's Center for iPS Cell Research and ... - Abu Dhabi Media Office - January 11th, 2024
- Abu Dhabi Stem Cells Center partners with Japan-based Kyoto University and Rege Nephro - ZAWYA - January 11th, 2024
- Shinobi Therapeutics Launches with Completion of $51M Series A to Advance Hypoimmune iPS-T Cell Therapy Platform - PR Newswire - December 16th, 2023
- Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple... - February 26th, 2023
- Cell Therapy - an overview | ScienceDirect Topics - December 20th, 2022
- Stem Cell Therapy for Parkinson's: Current Developments - Healthline - December 20th, 2022
- Cell and Gene Therapy World Asia Event - IMAPAC - December 20th, 2022
- Present and Future Perspectives on Cell Sheet-Based ... - Hindawi - December 20th, 2022
- Stem cell therapy side effects & risks: infections, tumors & more - November 18th, 2022
- Stem cell therapy for diabetes - PMC - PubMed Central (PMC) - November 18th, 2022
- Ethical issues in stem cell research and therapy - November 18th, 2022
- Amniotics led consortium selected for EIC-Pathfinder grant of 3.8 million from the European Innovation Council - Marketscreener.com - November 18th, 2022
- Ono Exercises Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors Generated from the Collaboration with Fate Therapeutics -... - November 10th, 2022
- Cell Rejuvenation and Cell Therapy | Cell Regeneration Perth - August 28th, 2022
- cGMP iPSCs & Cell Therapy Manufacturing | CDMO | I Peace, Inc. - August 28th, 2022
- Stem cell therapy for knees: fact-check, costs, risks - August 28th, 2022
- Global Cell Banking Outsourcing Market to Grow at a CAGR of ~18% during 2022-2031; Market to Expand Owing to the Development of Advanced Cell... - August 28th, 2022
- Twenty-Five Years After My House Call To Dolly: What Have We Learned About Cloning And How Did We Learn It? - Forbes - August 3rd, 2022
- Construction of a novel signature and prediction of the immune landscape in gastric cancer based on necroptosis-related genes | Scientific Reports -... - August 3rd, 2022
- Gene & Cell Therapy FAQs | ASGCT - American Society of Gene & Cell ... - June 28th, 2022
- The benefits and risks of stem cell technology - PMC - June 28th, 2022
- Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a... - June 28th, 2022
- Rising Focus on Exploring Potential of Stem Cells as Therapeutic Tools in Drug Targeting and Regenerative Medicine to Fuel Revenue Growth of Stem... - January 17th, 2022
- SC21- 21st century cellular medicines specialists - The Thaiger - November 21st, 2021
- Introduction to Stem Cell Therapy - PubMed Central (PMC) - October 15th, 2021
- Stem cells: Therapy, controversy, and research - October 15th, 2021
- How much does stem cell therapy cost in 2021? - The Niche - October 15th, 2021
- "Stem cell-based therapeutics poised to become mainstream option - BSA bureau - October 5th, 2021
- Insights on the Stem Cell Banking Global Market to 2026 - by Product Type, Service Type, Bank Type, Utilization, Application and Region - WFMZ... - July 20th, 2021
- Base Editing as Therapy for Common Inherited Lung and Liver Disease Shows Promise - Clinical OMICs News - July 20th, 2021
- The Possibility Of New CAR-T Cell Therapy For Multiple Myeloma - Powdersvillepost.com - July 6th, 2021
- MoHAP, EHS reveal immunotherapy for cancer, viral infections at Arab Health 2021 - WAM EN - June 23rd, 2021
- Global Induced Pluripotent Stem Cells Market Analysis By Future Demand, Top Players, Industry Share Size, Revenue and Growth Rate Through... - May 1st, 2021
- Upcoming Opportunities in CAR T-cell Therapy Market: Future Trend and Analysis of Key Segments and Forecast 2021 to 2026 NeighborWebSJ -... - May 1st, 2021
- Stem Cell Therapy Market to Score Past US$ 40.3 Billion Valuation by 2027: At a CAGR of 21.1% KSU | The Sentinel Newspaper - KSU | The Sentinel... - February 6th, 2021
- Research and therapy with induced pluripotent stem cells ... - December 19th, 2020
- Global Induced Pluripotent Stem Cells (iPSCs) Market Expectable to Exceed Global Market Revenue, Size, Segments and Market Competition Trend to... - December 14th, 2020
- Evotec and Sartorius Partner with Start-Up Curexsys on IPSC-Based Therapeutic Exosome Approach - BioSpace - December 10th, 2020
- A Potential Therapy for One of the Leading Causes of Heart Disease - PRNewswire - December 10th, 2020
- Multiple sclerosis iPS-derived oligodendroglia conserve their properties to functionally interact with axons and glia in vivo - Science Advances - December 6th, 2020
- The Stem Cell-Derived Cells market to Scale new heights in the next decade - Khabar South Asia - November 27th, 2020
- The Stem Cell-Derived Cells Market to witness explicit growth from 2019 and 2029 - The Haitian-Caribbean News Network - November 27th, 2020
- Stem Cells Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Industry Trends Adopted by the Competitors | (2020-2027),... - November 26th, 2020
- Stem Cells Market 2020: Rising with Immense Development Trends across the Globe by 2027 - The Market Feed - November 26th, 2020
- U.S. engineering firms ride on waves of innovation - Building Design + Construction - November 26th, 2020
- The Stem Cell-Derived Cells market to be in conjunction to growth from 2020 to 2030 - PRnews Leader - October 28th, 2020
- Stem Cell-Derived Cells Market to Expand at a Healthy CAGR of XX% Between and 2019 2029 - Eurowire - October 25th, 2020
- Stem Cell-Derived Cells Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2019 - 2029 - Stock Market Funda - October 4th, 2020
- Ghosh Addresses Brentuximab Vedotin Use in Advanced Hodgkin Lymphoma - Targeted Oncology - September 30th, 2020
- Global Induced Pluripotent Stem Cells (iPSCs) Market 2020 Manufacturer Analysis, Technology Advancements, Industry Scope and Forecast to 2027||Fate... - September 22nd, 2020
- Convergence: EMA close to finalizing guidance for advanced therapies - Regulatory Focus - September 18th, 2020
- Researchers ID Role of Protein in Development of New Hearing Hair Cells - Lab Manager Magazine - September 18th, 2020
- In-depth Research On Media, Sera And Reagents In Biotechnology Market Insights, And Forecast Till 2018-2023 - Scientect - September 6th, 2020
- Optimized Freezing Solutions for Clinical Application of Cell Therapy Products - technologynetworks.com - September 2nd, 2020
- Stem Cell-Derived Cells Market Forecast to 2025: Global Industry Analysis by Top Players, Types, Key Regions and Applications - The Scarlet - September 2nd, 2020
- Cell Therapy Processing Market is Booming Worldwide to Show Significant Growth by 2026 Cell Therapies Pty Ltd,Invitrx Inc.,Lonza Ltd,Merck & Co.,... - August 21st, 2020
- On the move at the OneAZ, Spencer Fane, UArizona - AZ Big Media - August 21st, 2020
- 3D Cell Cultures Industry Report 2020-2025: Impact of COVID-19 on the World of Cell Culture - PRNewswire - August 19th, 2020
- Stem Cell-Derived Cells Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2019 2029 - Owned - August 16th, 2020
- Opportunities in the Global Induced Pluripotent Stem Cell (iPS Cell) Industry - PRNewswire - August 12th, 2020
- Stem Cell-Derived Cells Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2019 2029 - Bulletin Line - August 2nd, 2020
- Hitachi and ThinkCyte to Develop an AI-driven Cell Analysis | ARC Advisory - ARC Viewpoints - July 8th, 2020
- Hitachi and ThinkCyte announce collaboration to develop an AI-driven cell analysis and sorting system - BioSpace - July 1st, 2020
- 2020-2024 Global Regenerative Medicine Market with Impact Analysis of COVID-19, Production, Revenue, Demand & Applications - Apsters News - July 1st, 2020
- Global Stem Cells Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By MRE - Cole of Duty - June 29th, 2020
- Global Regenerative Medicine Market: Size and Forecast with Impact Analysis of COVID-19 (2020-2024) - Cole of Duty - June 29th, 2020
- Global Stem Cell Therapy Market 2020: Size, Share, Growth Rate, Revenue and Volume, Key-Players, Top Regions and Forecast Till 2025 - Cole of Duty - June 22nd, 2020
- Global Regenerative Medicine Market (2020 to 2024) - Size & Forecast with Impact Analysis of COVID-19 - ResearchAndMarkets.com - Business Wire - June 18th, 2020
- Excellent growth of Human Embryonic Stem Cells Market- Comprehensive study by key players: Astellas Pharma Inc/ Ocata Therapeutics, Stemcell... - June 5th, 2020
- Global Stem Cell Partnering Deals Collection (2010-2020): Access to Headline, Upfront, Milestone and Royalty Data - PRNewswire - May 18th, 2020
- Global Stem Cell Partnering Terms and Agreements 2010-2020 - ResearchAndMarkets.com - Business Wire - May 17th, 2020
- AgeX Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update - Business Wire - May 16th, 2020
- Induced Pluripotent Stem Cell (iPSC) Media and Reagents ... - May 12th, 2020
- First iPS Cell Trial for Heart Disease Raises Excitement ... - May 12th, 2020
- Researchers use cell therapy to recover damaged brain areas in mice that suffered - Mirage News - April 26th, 2020
- Evotec Regains Global Rights to Beta Cell Replacement Therapy - Yahoo Finance - April 22nd, 2020
- Researchers restore sight in mice by turning skin cells into light-sensing eye cells - National Institutes of Health - April 15th, 2020
- Chimeric Antigen Receptor (CAR) T-Cell Therapy Market 2020: Professional Survey & Competitive Dynamics Mustang Bio Inc., iCell Gene Therapeutics,... - April 12th, 2020
- Evotec Expands its iPSC-Based Cell Therapy Platform EVOcells Through Licensing Agreement with panCELLa | More News | News Channels -... - April 6th, 2020
- Evotec partners with panCELLa to enhance cell therapy plaform - ITResearchBrief.com - April 6th, 2020